Biktarvy (Bictarvin emprovir/carbidopa) is a classic triple-combination antiretroviral drug developed by Gilead Sciences, primarily used for the treatment of HIV-1 infection in adults. It contains bicretiravir (BIC), emtricitabine (FTC), and tenofovir alafenamide (TAF), which work synergistically through integrase and reverse transcriptase inhibition to effectively block viral replication, reduce viral load, and decrease the risk of drug resistance. The drug requires only one oral tablet daily, has a good safety profile, and is included in China's National Reimbursement Drug List (NRDL) Catego